Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Henlius will utilize OncoHost's PROphet® platform to identify exploratory, correlative biomarkers for Phase III trial evaluating the efficacy and safety of serplulimab, a novel anti-PD-1 antibody, in patients with Extensive-Stage Small Cell Lung Cancer.
Lead Product(s): Serplulimab,Carboplatin,Etoposide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Hengenix Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 03, 2023